The short version
If your sex life changed after starting an antidepressant, you are not imagining it, and you are not alone. Sexual side effects are a recognised, listed effect of SSRIs and SNRIs. They can show up as lower desire, numbness, delayed or absent orgasm, or erection trouble. Many people never mention it, partly because they assume it is just part of the deal, and partly because they worry that raising it means giving up a medicine that is helping.
This guide sets out what the sources we opened say, how uncertain some of it is, and what a prescriber may be able to discuss. The one firm rule: do not stop or change your medication on your own. The NHS and the UK medicines regulator both say so, and the reasons are covered below. Claim strength is labelled throughout as strong, moderate, emerging, contested or unevidenced. This is educational information, not individual medical advice, and it gives no doses.
How common is it, really?
Reviews agree that sexual dysfunction is a common adverse effect of antidepressants, and that it is under-recognised. A 2026 targeted scoping review of 65 studies describes it as common and potentially under-recognised, particularly with SSRIs and SNRIs. A 2025 narrative review lists the typical pattern as decreased libido, difficulty with arousal and erection, and delayed or absent orgasm. Evidence label: STRONG that the effect exists and is common.
A single reliable percentage is harder. The best-known meta-analysis (Serretti and Chiesa, 2009) pooled studies that asked about sexual function directly with questionnaires. It found treatment-emergent dysfunction in a range of 25.8% to 80.3% of patients across the drugs that differed from placebo, with sertraline, venlafaxine, citalopram, paroxetine and fluoxetine among those listed. The authors themselves caution that mixing open-label studies and different scales could reduce the significance of their findings. Treat that range as a sign of how much it varies by drug and by method, not as a number that applies to you.
Method matters a great deal. A 2026 narrative review notes that patients often do not raise sexual concerns unless asked directly, so spontaneous reports undercount it, and it recommends validated questionnaires over informal questioning. The same pattern is why ranges in the literature are so wide. Some drugs in the 2009 analysis, including bupropion, mirtazapine and agomelatine, did not differ from placebo. That is a comparison across studies, not a promise about any individual.
Is it the medicine or the depression?
Both can be involved, which is why a prescriber will usually try to untangle it. Low desire, reduced arousal and trouble with orgasm can be part of depression and anxiety themselves. The 2026 Frontiers review points out that sexual dysfunction frequently precedes drug treatment in depressive illness, and that desire may improve with recovery alone. A 2025 review makes the opposite point: what it describes is an adverse effect of the drug, distinct from the reduced libido seen in the natural course of depression.
Practical clues a clinician may ask about are timing (did it begin soon after starting or after a dose change?), what your sex life was like beforehand, and whether other causes such as other medicines, alcohol, relationship stress, hormones or cardiovascular and diabetes issues could be involved. New erection problems in particular can have causes unrelated to the antidepressant, including early cardiovascular disease, so they deserve a medical check rather than an assumption.
Never stop or change medication on your own
The NHS says not to stop taking an antidepressant suddenly or without talking to your doctor first, and that your doctor can help agree a plan to reduce the dose gradually. In its 2025 announcement on this very issue, the UK medicines regulator (MHRA) tells people to keep taking their medicine as prescribed and not to change treatment without first speaking to a doctor or mental health professional. Its October 2026 Drug Safety Update repeats that patients should not stop without first speaking to their healthcare professional.
The reasons are practical. Stopping suddenly can cause discontinuation symptoms, and the depression or anxiety the medicine is treating can return. One 2026 review notes that if a dose is cut to improve sexual function, symptom recurrence may outweigh the gains, and that planned drug holidays are generally not preferred because they can provoke discontinuation symptoms, relapse or missed doses. Whether to adjust, switch or add anything is a decision to make with the prescriber who knows your history. A pharmacist or GP is a reasonable first stop.
What a prescriber may discuss
We cannot and do not recommend any of the following. This is what the reviews we opened describe as options a prescriber may weigh up, and in all cases the evidence is described as limited or still developing.
The 2026 scoping review lists dose reduction, switching to a lower-risk agent, and adding a PDE5 inhibitor or bupropion as strategies with some supporting evidence, while noting that optimal strategies remain incompletely defined. A 2025 review of management reports that switching to an antidepressant with a more favourable side-effect profile may help some people, particularly if the first treatment was not controlling the underlying condition, that bupropion as an add-on shows promise, and that data on other options are conflicting or scarce. A French clinical overview (abstract) groups the pharmacological approaches into tapering, maintenance and optimising treatment, and stresses tailoring to the person. The 2026 Frontiers review adds that bupropion augmentation has the most consistent support among antidepressant-related strategies, that PDE5 inhibitors may help erections but do not directly treat low desire or anorgasmia, and that cardiovascular and nitrate checks are needed.
Evidence label: MODERATE for the idea that some of these approaches help some people, because the studies are small and varied, and the reviews themselves call the evidence base limited. Whether any suits you depends on your diagnosis, other medicines, health and goals, which only your prescriber can weigh.
Talking, therapy and non-drug approaches
The same reviews describe psychoeducation, supportive psychotherapy, couples work and sex therapy as options when shame, avoidance or relationship strain are part of the picture, while noting that their evidence base is less robust than for drug strategies. The 2026 scoping review also says exercise, psychotherapy and mindfulness-based strategies have shown preliminary benefit in selected studies and may serve as adjuncts. Evidence label: EMERGING.
We found no trial testing sensate-focus exercises, breath work or any tantric or somatic practice specifically for antidepressant-related sexual dysfunction, so we make no claim that they work for it. At the level of mechanism, contemplative and somatic practices overlap with mindfulness, breath and sensate-focus approaches, which aim to reduce performance pressure and increase attention to sensation. That is a reasonable thing to explore alongside medical care, never instead of it. See our guides on sensate focus and on the mindfulness evidence for sexual anxiety for the wider picture.
Post-SSRI sexual dysfunction: recognised, but contested
Some people report that sexual problems continue after they stop the medicine, a pattern often called post-SSRI sexual dysfunction (PSSD). Regulators have responded. In 2019 the European Medicines Agency's safety committee recommended that product information for SSRIs and SNRIs state that there have been reports of long-lasting sexual dysfunction that continued despite discontinuation. The Australian TGA aligned SSRI and SNRI product information in 2024 (as reported by USANZ, June 2024), and the MHRA has said the term PSSD will be added to patient leaflets for affected antidepressants. The NHS also states that for some people sexual problems may carry on after stopping.
What regulators have not said is how often it happens or exactly why. The TGA says persistent cases are thought to be rare but are likely under-reported, and that their prevalence is not known; reported durations run from weeks to years. A 2025 qualitative study of ten people recruited through an advocacy group (abstract) reported that participants described suffering and alienation and felt clinicians often lacked awareness. That is real lived experience, but it is a small, self-selected sample and cannot tell us how common PSSD is. A 2026 review (abstract) describes diagnosis as clinical and notes that no approved treatments exist. Evidence label: CONTESTED as a defined condition with known frequency and cause; STRONG that regulators now acknowledge reports of persistence.
If you think this is happening to you, say so to your prescriber. They can record it, and in the UK you can report suspected side effects through the Yellow Card scheme.
When to see a professional
Book a GP or pharmacist conversation if sexual changes are troubling you or your partner, if you are thinking of stopping, or if you have new pain, a new erection problem or other physical symptoms. Ask directly: the reviews note that clinicians often do not raise it and patients often do not either. Useful questions include whether the change fits the medicine, whether timing or a dose review makes sense, whether another option exists, and what the relapse risk would be.
Seek urgent help if low mood is worsening, if you have thoughts of suicide or self-harm, or if you feel unsafe. The MHRA is adding a boxed warning about suicidal thoughts to antidepressant leaflets: if you have new or worsening suicidal thoughts, especially soon after starting, stopping or changing a dose, seek urgent medical attention. In Australia, Lifeline is on 13 11 14 and says to call Triple Zero (000) if life is in danger. In the UK and Ireland, Samaritans is free on 116 123, 24 hours a day. In the United States, call or text 988. These services are not only for the moment of crisis, and they are free. Stopping medication abruptly because of sexual side effects, and then feeling much worse, is a good reason to call a doctor straight away.
What this guide does not cover
This guide does not advise on any dose, switch, taper or add-on, and it cannot say whether a given symptom is caused by your medicine. It does not cover antipsychotics, mood stabilisers or the sexual effects of other conditions, and we could not open some primary regulator pages directly, so quoted regulatory wording is limited to the pages we did open. Reviews of this topic are mostly narrative, small or based on self-report. If your decision is about a specific medicine, your prescriber and pharmacist hold the information that matters.